Text Size
19 studies found for:    Open Studies | spectrum pharmaceuticals

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Recruiting Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)
Condition: Follicular Lymphoma
Interventions: Drug: Zevalin;   Drug: Rituximab
2 Not yet recruiting Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn
Condition: Non Hodgkin's Lymphoma
Interventions: Drug: Fusilev;   Drug: Folotyn
3 Recruiting Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Condition: Peripheral T-cell Lymphoma
Intervention:
4 Recruiting Safety and Efficacy Study of High Dose Melphalan HCL for Injection (Propylene Glycol-Free) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation
Condition: Multiple Myeloma
Intervention: Drug: High-Dose Melphalan HCL for Injection (Propylene Glycol-Free)
5 Recruiting Maximum Tolerated Dose Study of Belinostat (PXD-101)in Combination With Paclitaxel Plus Carboplatin in Chemotherapy-Naive Patients With Stage IV Non-Small-Cell Lung Cancer (NSCLC)
Condition: Stage IV Non-small Cell Lung Cancer
Intervention: Drug: Belinostat, Carboplatin, Paclitaxel
6 Not yet recruiting Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC)
Condition: Non Small Cell Lung Cancer (NSCLC)
Interventions: Drug: SPI-1620 & Docetaxel;   Drug: Docetaxel
7 Recruiting Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Condition: Neutropenia
Interventions: Drug: HM10460A (45 μg/kg);   Drug: HM10460A (135 μg/kg);   Drug: HM10460A (270 μg/kg);   Drug: Pegfilgrastim 6mg
8 Not yet recruiting Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer
Condition: Advanced Cancer
Intervention: Drug: Belinostat
9 Recruiting Study of Pralatrexate Versus Observation Following CHOP-based Chemotherapy in Previously Undiagnosed Peripheral T-cell Lymphoma Patients
Condition: Peripheral T-cell Lymphoma
Intervention: Drug: Pralatrexate Injection
10 Recruiting Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Conditions: Diffuse Large B-cell Lymphoma;   Follicle Center Lymphoma
Intervention: Drug: Zevalin (ibritumomab tiuxetan)
11 Recruiting Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer
Condition: Biliary Cancer
Intervention: Drug: SPI-1620 & Docetaxel
12 Not yet recruiting Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn®
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Folotyn;   Drug: Fusilev
13 Recruiting International,Multi-Center,Open Label,Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot in Men With Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Ozarelix;   Drug: Goserelin
14 Recruiting Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)
Condition: Peripheral T-cell Lymphoma
Interventions: Drug: Belinostat;   Drug: CHOP
15 Recruiting Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)
Conditions: Leukemia;   Lymphoma
Interventions: Drug: Rituximab;   Drug: 111In Ibritumomab;   Procedure: Planar Scintigraphy Imaging;   Drug: 90Y IbritumomabTiuxetan;   Drug: Fludarabine;   Drug: Bendamustine;   Drug: Thymoglobulin;   Drug: Tacrolimus;   Drug: Methotrexate;   Drug: Mycophenolate;   Drug: G-CSF;   Procedure: Stem Cell Transplantation
16 Recruiting Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma
Condition: Lymphoma, Follicular
Interventions: Drug: Bendamustine;   Drug: Rituximab;   Radiation: Y-90 ibritumomab
17 Recruiting Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
Conditions: Refractory Non Hodgkin Lymphoma;   Relapsed Non Hodgkin Lymphoma
Interventions: Biological: rituximab;   Biological: ibritumomab tiuxetan;   Biological: anti-thymocyte globulin;   Radiation: total nodal irradiation;   Procedure: peripheral blood stem cell transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Other: laboratory biomarker analysis
18 Recruiting Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma
Condition: Mantle-Cell Lymphoma
Intervention: Drug: Rituximab, Bortezomib,Y90 ibritumomab tiuxetan
19 Recruiting Pheno- & Genotyping POF (WHO III)
Conditions: Premature Ovarian Failure (POF);   Incipient Ovarian Failure;   Poor Response After Ovarian Hyperstimulation;   Early Menopause;   Hypergonadotropic Amenorrhea
Intervention:
To Top

† Indicates status has not been verified in more than two years